Skip to main navigation Skip to primary sidebar Skip to footer 240.243.1201 info@glycomimetics.com Careers Contact Us Investor Relations ABOUT US PATIENTS PIPELINE TECHNOLOGY & PUBLICATIONS COLLABORATIONS INVESTORS INVESTOR RELATIONS Corporate Profile At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline. Volume 3:23 am EST on Dec 02,2021 Copyright Nasdaq. Minimum 15 minutes delayed. NEWS November 24, 2021 GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) November 23, 2021 Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML November 22, 2021 GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs EVENTS Nov 17, 2021 11:20 AM GMT Jefferies London Healthcare Conference Listen to webcast Nov 15, 2021 3:20 PM EST Stifel 2021 Virtual Healthcare Conference Listen to webcast Nov 2, 2021 8:30 AM EDT GlycoMimetics 3rd Quarter 2021 Earnings Call Listen to webcast PRESENTATIONS CORPORATE PRESENTATION VIEW ALL NEWS VIEW ALL EVENTS Shareholder Tools PRINT PRINTED MATERIALS EMAIL ALERTS RSS SEARCH Footer Questions? Contact GlycoMimetics Today GET IN TOUCH ©2021 GlycoMimetics All rights reserved. Website Design & Development: Graphic Beans Site Map | Terms of Use | Privacy | Contact Us